About this trial
The aim of this study is to evaluate the role of low dose injectable progesterone in triggering ovulation.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age from 20 to 35 years.
Infertile women.
Basal follicle-stimulating hormone (FSH) level <10 mIU/ml.
Disqualifiers
Poor ovarian reserve.
Immunological disease.
Endometriosis.
Uterine abnormality.
Trial design
Parallel
Treatments tested in this trial
Progesterone
DrugWomen will receive low dose progesterone 5 mg intramuscularly as a study group. (Letrozole 2.5 mg/day will be given from cycle day 3 onwards for only 5 days).
Placebo
DrugWomen will receive placebo as a control group. (Placebo 2.5 mg/day will be given from cycle day 3 onwards for only 5 days).
Treatment groups
Trial outcomes
Primary outcomes
Incidence of ovulation rates
Incidence of ovulation rates will be recorded.
Secondary outcomes
Follicle stimulating hormone (FSH)levels
Follicle stimulating hormone (FSH) will be measured on day 3, day 8-10 and day 10-12 of the menstrual cycle, as well as the day of trigger and oocyte retrieval.
Luteinizing hormone (LH)levels
Luteinizing hormone (LH) will be measured on day 3, day 8-10 and day 10-12 of the menstrual cycle, as well as the day of trigger and oocyte retrieval).
Estradiol (E2) levels
Estradiol (E2) will be measured on day 3, day 8-10 and day 10-12 of the menstrual cycle, as well as the day of trigger and oocyte retrieval.
Progesterone levels
Progesterone levels will be measured on day 3, day 8-10 and day 10-12 of the menstrual cycle, as well as the day of trigger and oocyte retrieval.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.